ChromaDex Clinical Trial Studying NIAGEN® Well Underway,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
ChromaDex Clinical Trial Studying NIAGEN® Well Underway, With Eight Additional Collaborative Human Studies Active

IRVINE, Calif., July 20, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ: CDXC ), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that the study of NIAGEN ® - nicotinamide riboside is well underway having achieved 50% enrollment of its 140 total participants.

This trial is examining the effective dose range of NIAGEN ® to increase NAD+ and NAD+ metabolite concentrations in the body with consistent use over time. The study design is an 8-week, randomized, double-blind, placebo controlled parallel trial in 140 healthy adults ranging in age from 40-60. Study participants in the active group receive between 100-1000mg per day. Additional endpoints investigated include: C-reactive protein, total cholesterol, LDL, HDL and triglycerides and amino acid panels, NAD+ levels in muscle, mitochondrial biomarkers, and the effects of NR on resting metabolic rate.

Najla Guthrie, President and CEO of the contract research organization responsible for coordinating the trial, KGK Synergize Inc. commented, “We have been very pleased that enrollment has gone smoothly. If things continue along this path we would be on track to have results collected around December.”

In addition to this trial, there are eight other collaborative human studies actively underway which are sponsored by entities other than ChromaDex. There are also four additional human trials which are also estimated to begin sometime over the next 6 to 9 months. Frank Jaksch, Jr., CEO and co-founder of ChromaDex stated, “These are exciting times for the ChromaDex team and the scientific community at large. New research seems to be publishing on almost a weekly basis, further building the body of evidence around the effectiveness of NR and the importance of boosting NAD+. We look forward to sharing more about our study results in early 2017.”

This is the second human clinical study sponsored by ChromaDex. The first human clinical trial announced in February 2015 demonstrated that a single oral dose of NIAGEN ® is a safe, effective NAD+ precursor in humans.

About NAD+: NAD+ is an essential metabolite which activates cellular metabolism and cellular energy production within the “powerhouses of the cell” - the mitochondria. The mitochondria’s key role within the cell is to convert nutrients such as fats, proteins and carbohydrates into energy which is necessary to power all bodily systems and functions. Decreased efficiency in the mitochondria is linked to a number of adverse health conditions such as metabolic syndrome.

A study by researchers from Harvard Medical School  conducted in conjunction with the National Institute on Aging and published in December 2013 in  Cell  demonstrated that mitochondrial dysfunction (a hallmark of aging) in aging mice is due to a disruption in the communication between the cell’s nucleus and its mitochondria. The study further showed that a reduction in NAD+ levels is responsible for this disruption. Excitingly, the study demonstrated that this mitochondrial dysfunction is readily reversible by the administration of a NAD+ precursor. The study reported that "1 week of treatment with a compound that boosts NAD+ levels is sufficient to restore the mitochondrial homeostasis and key biochemical markers of muscle health in a 22-month-old mouse to levels similar to a 6-month-old mouse," indicating that the mitochondria were “rejuvenated,” and that some aspects of aging may be theoretically reversible.

About the NAD+ precursor (or booster), Nicotinamide Riboside (NR): Sometimes referred to as “The forgotten B 3 ," the benefits of NR remained unknown for years after its initial discovery and classification as a vitamin B 3, due to the lack of advanced understanding of nucleotide science. It was not until 2004 that this hidden gem resurfaced after Dr. Charles Brenner, then professor at Dartmouth, identified the missing link as to how NR becomes NAD+. This discovery also suggested that NR also had the ability to boost NAD+ in a more energy efficient way than could be achieved with its B 3 cousins, niacin or nicotinamide, leaving the body extra energy to focus on its critical needs and processes. NR’s unique energy sparring ability to produce NAD+ has excited the scientific community around the world. This excitement has led to 70 material transfer agreements to top research institutions all studying the effects of NR in separate therapeutic endpoints. The body of evidence continues to build as researchers make seminal discoveries characterizing the unique properties of NR in a wide range of health benefits, including increased mitochondrial health resulting in improved cellular energy production, increased muscle endurance, neuroprotection, improvements in longevity, protection against weight gain when consuming a high fat diet , protection against oxidative stress and improvement of blood glucose and insulin sensitivity. NIAGEN ® is the world’s first and only, nature identical form of NR commercially available today.

Dr. Brenner now sits on the scientific advisory board at ChromaDex.

About ChromaDex: ChromaDex leverages its complementary business units to discover, acquire, develop and commercialize patented and proprietary ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. In addition to our ingredient technologies unit, we also have business units focused on natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (known as Spherix Consulting). As a result of our relationships with leading universities and research institutions, we are able to discover and license early stage, IP-backed ingredient technologies. We then utilize our in-house chemistry, regulatory and safety consulting business units to develop commercially viable ingredients. Our ingredient portfolio is backed with clinical and scientific research, as well as extensive IP protection. Our portfolio of patented ingredient technologies includes NIAGEN ® nicotinamide riboside; pTeroPure ® pterostilbene; PURENERGY ® , a caffeine-pTeroPure ® co-crystal; ProC3G ® , a natural black rice containing cyanidin-3-glucoside; IMMULINA ™ , a spirulina extract; and anthocyanins derived from a domestically-produced, water-extracted purple corn. To learn more about ChromaDex, please visit www.ChromaDex.com .

Forward-Looking Statements: This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to the timing and results of the study of NIAGEN ® - nicotinamide riboside for long term use. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release, including, without limitation, the timing and results of the study of NIAGEN ® - nicotinamide riboside for long term use, due to the risks and uncertainties inherent in ChromaDex's business. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended January 2, 2016, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov . Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

ChromaDex Public Relations Contact: Breah Ostendorf, Director of Marketing 949-537-4103 breaho@chromadex.com ChromaDex Investor Relations Contact: Andrew Johnson, Director of Investor Relations 949-419-0288 andrewj@chromadex.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Kansai Powers Up US Grid with Bold Investment Move

Updated Category News Views 128

Betting Big on Battery Storage Let's unpack this big move by Kansai Electric. Anytime a major player like Kansai steps out of its home turf, folks better pay attention. Looks like Kansai's gotten cozy with Elevate and ArcLight, nabbing a minority stake in Prospect Power. This ain't your average widget factory—it's a beefy 150MW/600MWh battery energy storage facility in...

Continue Reading
RBC Grabs Top Honors for Sustainable Investing Leadership

Updated Category News Views 154

A New Feather in RBC's Cap RBC Wealth Management has racked up more accolades, crowned as the Best Private Bank in Canada and celebrated for its prowess in impact and sustainable investing on the global stage. These distinctions flew in courtesy of the PWM Global Private Banking Awards—a heavyweight recognition in the wealth management world. Award Winning Strategy in...

Continue Reading
Radiate Holdco's Q3 Results: What We Know Now

Updated Category News Views 69

Digging Into Third Quarter Highlights Radiate Holdco, LLC has just thrown its third-quarter financial hat into the ring, stirring up some interest in the world of FLFO secured notes and senior notes. The folks in Princeton, N.J., sure know how to keep things exclusive—this intel is only for those holding their Notes or in the pretty exclusive club of qualified...

Continue Reading
Kinross Gold Faces Class Action Over Misleading Forecasts

Updated Category News Views 68

A Golden Opportunity Gone Wrong Well, it looks like Kinross Gold Corporation (NYSE: KGC) has stuck its foot in it again. This time, they're in hot water over claims that don't exactly hold up under scrutiny. If you're holding KGC, you've probably heard about the fresh class action lawsuit alleging they misled investors about their production targets. Naturally, the...

Continue Reading
SKE Capitalizes on Halloween Events in London

Updated Category News Views 120

SKE's Bold Step into London's Halloween Vibe Hah! Who would've thought that vaping and Halloween could be a match made in heaven? This year, SKE threw its hat into the ring and wrestled for attention in London’s bustling Halloween music scene. Imagine an entire warehouse pulsing not just with beat-heavy electronic music, but the energy of vaping enthusiasts courtesy of...

Continue Reading
Sabre Unveils AI Travel Tech: A Bold New Frontier

Updated Category News Views 65

Sabre's Game-Changing AI Travel Integration I'm no stranger to bold moves in the travel industry, but what Sabre's rolling out tomorrow might just be the biggest leap we've seen in a while. They're unleashing what's called the first global travel plug-in within Grok Bot, marking a significant shake-up in the travel tech sphere. Too many tech upgrades in this business...

Continue Reading
Elah Holdings' Q3 2026 Report Sparks Investor Interest

Updated Category News Views 63

Elah Holdings Drops Their Q3 2026 Numbers Eat your heart out, folks—Elah Holdings has just dropped their third quarter report for 2026, and it caught some eyes. This ain't your run-of-the-mill, brush-right-past-it release. They're out there, waving their flag high in the competitive marketplace, trying to tell us they mean business. If you missed the announcement, they...

Continue Reading
Loyalty Programs Cut $1500 Annually for Consumers

Updated Category News Views 122

Loyalty Programs: An Essential Tool for Households In a world where every dollar counts, retail loyalty programs have become more than just a marketing strategy—they're lifelines for American households scraping through each month. According to fresh research by the Retail Industry Leaders Association (RILA) and conducted by market research leader Circana, these...

Continue Reading
Hermes AI: A New Era in Market Analysis?

Updated Category News Views 111

Revolution or Just Another App? In a world where stock market insights are as cryptic as hieroglyphs to the average Joe, here comes the Hermes AI Analyzer, breaking onto the scene and promising to translate Wall Street's complex lingo into plain, simple language. It's the brainchild of Turkish engineer Umut Tugrul, who has spent decades in the trenches of software...

Continue Reading
equipifi's BNPL Shop: New Ammo for Credit Unions

Updated Category News Views 106

equipifi's 'Shop': The Big Play in Banking Look, here’s the deal—equipifi just lobbed a new grenade into the finance battlefield, arming credit unions and community banks with 'Shop', their own Buy Now, Pay Later (BNPL) platform. The goal? To put them toe-to-toe with the big fintech wolves—something these smaller guys desperately needed. It's a meaty move, no...

Continue Reading

Top 5 Most Recently Viewed Articles

Radiant Striping's Community Commitment through Service Initiatives

Updated Category News Views 144

Radiant Striping's Charitable Impact on the Community Radiant Striping, a veteran-owned company, is making waves in their community through generous donations of parking lot striping and other services to local organizations. It's not just about the perfect paint job; it’s about building safer, more welcoming spaces for families and visitors alike. A Mission Rooted in...

Continue Reading
Supernus Pharmaceuticals Announces Participation in Key Healthcare Event

Updated Category News Views 86

Supernus Pharmaceuticals' Participation in the Healthcare Conference Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a dedicated biopharmaceutical company, is excited to announce its upcoming participation in a significant healthcare conference. The conference will take place soon, and prominent figures from the company, including Jack Khattar, President and CEO, are set...

Continue Reading
CTC Celebrated as Top Veteran-Friendly Employer in 2024

Updated Category News Views 70

Concurrent Technologies Corporation Recognized in 2024 Concurrent Technologies Corporation (CTC) is thrilled to announce its inclusion in the U.S. Veterans Magazine’s Top Veteran-Friendly Employers list for 2024. This achievement marks the fourth consecutive year that CTC has received this important recognition. How U.S. Veterans Magazine Evaluates Employers Each year,...

Continue Reading
Chimerix Announces Inducement Grant of Stock Options

Updated Category News Views 188

Chimerix Announces Inducement Grant of Stock Options Chimerix (NASDAQ:CMRX), a prominent biopharmaceutical company, has announced a notable inducement award for a newly hired employee. This grant includes non-statutory stock options totaling 150,000 shares of the company's common stock, underscoring Chimerix's dedication to attracting top talent in the competitive biotech...

Continue Reading
EarFun Showcases Cutting-Edge Wireless Audio Innovations

Updated Category News Views 620

Discover the Latest Innovations from EarFun at CES 2025 EarFun, a prominent name in wireless audio technology, is set to unveil a range of cutting-edge products that will redefine the audio experience. Their participation in CES 2025 promises to highlight significant advancements that cater to diverse listening needs. Innovative AI-Powered Features The spotlight will be...

Continue Reading